Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7713280 | 0.92 | GAA (0.55) | GAAMGAMSIMGAM2SOAT1 | |
| SCHEMBL6958990 | 0.84 | GAA (0.48) | GAAMGAMSIMGAM2SOAT1 | |
| SCHEMBL9865139 | 0.82 | GAA (0.46) | GAAMGAMSIMGAM2SOAT1 | |
| SCHEMBL944132 | 0.81 | GAA (0.50) | GAAMGAMSIMGAM2SOAT1 | |
| SCHEMBL697911 | 0.81 | — | — | |
| SCHEMBL28103296 | 0.81 | ALDH1A1 (0.38) | GAAMGAMSIMGAM2SOAT1 | |
| SCHEMBL9863845 | 0.81 | TSHR (0.41) | GAAMGAMSIMGAM2SOAT1 | |
| SCHEMBL6958983 | 0.80 | GAA (0.44) | GAAMGAMSIMGAM2SOAT1 | |
| SCHEMBL2105768 | 0.79 | — | — | |
| SCHEMBL1413000 | 0.79 | GAA (0.48) | GAAMGAMSIMGAM2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114131923-B | Method for producing polyurethane three-dimensional objects from materials having multiple hardening mechanisms | 卡本有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-111194217-B | 4 '-fluoro-2' -methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication | 里伯赛恩斯有限责任公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-115195104-B | Dual precursor resin system for additive manufacturing with dual cure resins | 卡本有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-115195104-A | Dual precursor resin system for additive manufacturing with dual cure resins | 卡本有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114734628-A | Method for producing three-dimensional objects from materials with multiple hardening mechanisms | 卡本有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-108139665-B | Dual precursor resin system for additive manufacturing with dual cure resins | 卡本有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114131923-A | Method for producing three-dimensional objects of polyurethane from materials with multiple hardening mechanisms | 卡本有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-106687861-B | Method for producing three-dimensional objects from materials with multiple hardening mechanisms | 卡本有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-106796392-B | Method for producing three-dimensional objects of polyurethane from materials with multiple hardening mechanisms | 卡本有限公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-107077064-B | Polyurethane resin with multiple hardening mechanisms for producing three-dimensional objects | 卡本有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-102498113-A | Macrocyclic inhibitors of jak | HOFFMANN LA ROCHE | 2012-06-13 | — | — | CN | disclosed |
| CN-102482326-A | Method for isolating therapeutic peptides | CORDEN PHARMA COLORADO INC | 2012-05-30 | — | — | CN | disclosed |
| CN-102414220-A | Insulinotropic peptide synthesis using solid and liquid phase combination techniques | HOFFMANN LA ROCHE | 2012-04-11 | — | — | CN | disclosed |
| CN-101903400-A | Insulinotropic peptide synthesis using solid and liquid phase combination techniques | HOFFMANN LA ROCHE | 2010-12-01 | — | — | CN | disclosed |
| CN-101646679-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE CH | 2010-02-10 | — | — | CN | disclosed |
| CN-101560167-A | Alpha-n-methylation of amino acids | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | CN | disclosed |
| CN-101384599-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| CN-101384596-A | Heterocylic antiviral compounds | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| CN-1878783-A | Process for preparing antiviral nucleoside derivatives | ROCHE PALO ALTO LLC (CH) | 2006-12-13 | — | — | CN | disclosed |
| US-20050080252-A1 | Process for preparing antiviral nucleoside derivatives | ROCHE PALO ALTO LLC | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080252-A1 | Process for preparing antiviral nucleoside derivatives | UMPS, ADAR, DUT | GAA 1423/4885MGAM 2559/4885SI 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.